SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 17, 2008. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
There are no material changes to financial performance reported in this filing. The only reported activity is an increase in Ordinary Share ADR holdings by specific individuals following the reinvestment of dividends paid on January 10, 2008.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly details compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Type: Reinvestment of dividends into Ordinary Share ADRs.
- Transaction Price: $54.11 per ADR.
- Dividend Date: January 10, 2008.
- Notified Individuals: Dr. JP Garnier (748.45 ADRs), Mr. D J Phelan (160.38 ADRs), and Mr. D M Stout (77.67 ADRs).
- Regulatory Basis: Notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).